Physician profile
Nadia Ovchinsky
NPI 1144349796
$40,561.55
in general payments reported to CMS, 2019-2025
12 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Pediatric Transplant Hepatology provider received nationally (typical 2025 total: $425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.76 · 2020: $14.66 · 2021: $14.95 · 2022: $3,358 · 2023: $10K · 2024: $26K · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $14K · Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,731 · Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,577.48 |
| Consulting Fee | $13,336.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,731.23 |
| Food and Beverage | $1,509.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $23,531.55 | 2022-2024 | Bylvay |
| Mirum Pharmaceuticals, INC. | $5,277.80 | 2022-2025 | Livmarli |
| Ipsen Innovation | $3,735.00 | 2024 | Iqirvo |
| Ipsen Biopharmaceuticals, INC | $3,320.00 | 2024 | Bylvay |
| Boehringer Ingelheim International Gmbh | $1,750.00 | 2024 | |
| Alexion Pharmaceuticals, INC. | $1,340.00 | 2022 | |
| Ipsen Pharma Sas | $1,319.73 | 2024-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $145.99 | 2025 | Livdelzi |
| Abbvie INC. | $73.38 | 2019-2022 | |
| Genzyme Corporation | $47.80 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $14.73 | 2022 | |
| Travere Therapeutics, INC. | $5.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Ovchinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.